Molecular clonality assessment shows high performance to predict malignant B-cell non-Hodgkin's lymphoma using cytological smears.

Autor:	Roepman P; Pathologie DNA, Nieuwegein, The Netherlands., Boots CM; Pathologie DNA, Nieuwegein, The Netherlands., Scheidel KC; Pathologie DNA, Nieuwegein, The Netherlands., Sprong T; Pathologie DNA, Nieuwegein, The Netherlands., de Bruin P; Pathologie DNA, Nieuwegein, The Netherlands., de Weerdt O; Department of Hematology, St. Antonius Hospital, Nieuwegein, The Netherlands., Groenen PJ; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands., Kummer JA; Pathologie DNA, Nieuwegein, The Netherlands.
Jazyk:	angličtina
Zdroj:	Journal of clinical pathology [J Clin Pathol] 2016 Dec; Vol. 69 (12), pp. 1109-1115. Date of Electronic Publication: 2016 May 11.
DOI:	10.1136/jclinpath-2016-203757
Abstrakt:	Aims: Molecular PCR-based clonality analysis is helpful for identification of monoclonal B-cell or T-cell populations and to distinguish malignant lymphoma from reactive lymphoid hyperplasia. Typically, clonality assessment on fine-needle aspiration cytology (FNAC) requires freshly obtained aspirates, but the collection and processing of these samples are often challenging in daily practice. In this study, we assessed the routine diagnostic value of the EuroClonality/BIOMED-2 assay for B-cell clonality on air-dried archived Giemsa-stained smears. Methods: This study comprised a retrospective analysis of a consecutive diagnostic cohort of 192 FNAC samples from 184 patients with at least 2-year follow-up. The results from the clonality assay were integrated with cytomorphological assessment and evaluated for their accuracy in detecting malignant disease. EuroClonality expert re-evaluation was performed for all cases with ambiguous results and for cases in which the diagnosis did not match the follow-up data. Results: The clonality assay showed a high accuracy of 93% for detection of malignancy, with a sensitivity of 93% and a specificity of 92%. All 64 cases with monoclonal Ig heavy chain (IGH)/Ig kappa chain (IGK) rearrangements were confirmed malignant by histology or clinical follow-up. Expert re-evaluation changed the definite diagnosis for five cases (3%), mainly because of low signals or no proper duplicate results. We discuss and elucidate all cases for which the clonality results did not match the disease follow-up. Conclusions: This study showed that EuroClonality/BIOMED-2 assay can successfully be performed on cytological Giemsa-stained smears and inclusion in daily practice can assist in better identification of malignant lymphoma. (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu